124 related articles for article (PubMed ID: 25193233)
1. Luteolin from Flos Chrysanthemi and its derivatives: New small molecule Bcl-2 protein inhibitors.
Zheng CH; Zhang M; Chen H; Wang CQ; Zhang MM; Jiang JH; Tian W; Lv JG; Li TJ; Zhu J; Zhou YJ
Bioorg Med Chem Lett; 2014 Oct; 24(19):4672-4677. PubMed ID: 25193233
[TBL] [Abstract][Full Text] [Related]
2. Structural modification of luteolin from Flos Chrysanthemi leads to increased tumor cell growth inhibitory activity.
Yang C; Chen H; Lu S; Zhang M; Tian W; Wang M; Zhang L; Song Y; Shen A; Zhou Y; Zhu J; Zheng C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3464-7. PubMed ID: 27353532
[TBL] [Abstract][Full Text] [Related]
3. Selective synthesis of 7-O-substituted luteolin derivatives and their melanonenesis and proliferation inhibitory activity in B16 melanoma cells.
Yamauchi K; Fujieda A; Mitsunaga T
Bioorg Med Chem Lett; 2018 Aug; 28(14):2518-2522. PubMed ID: 29887353
[TBL] [Abstract][Full Text] [Related]
4. Regulation of IGF-I production and proliferation of human leiomyomal smooth muscle cells by Scutellaria barbata D. Don in vitro: isolation of flavonoids of apigenin and luteolin as acting compounds.
Kim DI; Lee TK; Lim IS; Kim H; Lee YC; Kim CH
Toxicol Appl Pharmacol; 2005 Jun; 205(3):213-24. PubMed ID: 15922007
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic activity of flavonoids from the flowers of Chrysanthemum morifolium on human colon cancer Colon205 cells.
Xie YY; Yuan D; Yang JY; Wang LH; Wu CF
J Asian Nat Prod Res; 2009 Sep; 11(9):771-8. PubMed ID: 20183323
[TBL] [Abstract][Full Text] [Related]
6. Flavonoid profile and antileukemic activity of Coreopsis lanceolata flowers.
Pardede A; Mashita K; Ninomiya M; Tanaka K; Koketsu M
Bioorg Med Chem Lett; 2016 Jun; 26(12):2784-2787. PubMed ID: 27155901
[TBL] [Abstract][Full Text] [Related]
7. 8-Chrysoeriol, as a potential BCL-2 inhibitor triggers apoptosis of SW1990 pancreatic cancer cells.
Zhang Y; Li Z; Min Q; Palida A; Zhang Y; Tang R; Chen L; Li H
Bioorg Chem; 2018 Apr; 77():478-484. PubMed ID: 29454280
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a small-molecule pBcl-2 inhibitor that overcomes pBcl-2-mediated resistance to apoptosis.
Song T; Yu X; Liu Y; Li X; Chai G; Zhang Z
Chembiochem; 2015 Mar; 16(5):757-65. PubMed ID: 25711460
[TBL] [Abstract][Full Text] [Related]
9. Response of Myeloid Leukemia Cells to Luteolin is Modulated by Differentially Expressed Pituitary Tumor-Transforming Gene 1 (PTTG1) Oncoprotein.
Chen PY; Tien HJ; Chen SF; Horng CT; Tang HL; Jung HL; Wu MJ; Yen JH
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29649138
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Wan Y; Dai N; Tang Z; Fang H
Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
[TBL] [Abstract][Full Text] [Related]
11. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening.
Enyedy IJ; Ling Y; Nacro K; Tomita Y; Wu X; Cao Y; Guo R; Li B; Zhu X; Huang Y; Long YQ; Roller PP; Yang D; Wang S
J Med Chem; 2001 Dec; 44(25):4313-24. PubMed ID: 11728179
[TBL] [Abstract][Full Text] [Related]
12. [Effects of total flavones of Chrysanthemum indicum on proliferation and apoptosis of human osteosarcoma Saos-2 cells].
Wei QQ; Yin CC; Zhou HY; He DW; Liang GS; Liu YL; Yin M
Zhong Yao Cai; 2013 Nov; 36(11):1823-7. PubMed ID: 24956827
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of luteolin, apigenin, chrysoeriol and diosmetin after oral administration of Flos Chrysanthemi extract in rats.
Chen Z; Kong S; Song F; Li L; Jiang H
Fitoterapia; 2012 Dec; 83(8):1616-22. PubMed ID: 22999990
[TBL] [Abstract][Full Text] [Related]
14. [Structure-activity relationship of diosgenin derivatives as Bcl-2 antagonists].
Jiang HP; Wu YK; Zheng W; Zeng CL; Fu WW; Fan JZ
Yao Xue Xue Bao; 2011 May; 46(5):539-47. PubMed ID: 21800541
[TBL] [Abstract][Full Text] [Related]
15. [Determination of main flavone glycosides in Flos Chrysanthemi and observation of factors influenced contents].
Hu BB; Wu ZS; Cai J; Jiang HD
Zhongguo Zhong Yao Za Zhi; 2006 Nov; 31(21):1772-5. PubMed ID: 17260789
[TBL] [Abstract][Full Text] [Related]
16. Dual Bcl-X
Daguer JP; Gonse A; Shchukin Y; Farrera-Soler L; Barluenga S; Winssinger N
Bioorg Med Chem; 2021 Aug; 44():116282. PubMed ID: 34216984
[TBL] [Abstract][Full Text] [Related]
17. Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells.
Lee EJ; Oh SY; Sung MK
Food Chem Toxicol; 2012 Nov; 50(11):4136-43. PubMed ID: 22926442
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.
Wang G; Nikolovska-Coleska Z; Yang CY; Wang R; Tang G; Guo J; Shangary S; Qiu S; Gao W; Yang D; Meagher J; Stuckey J; Krajewski K; Jiang S; Roller PP; Abaan HO; Tomita Y; Wang S
J Med Chem; 2006 Oct; 49(21):6139-42. PubMed ID: 17034116
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of luteolin against apoptosis induced by 6-hydroxydopamine on rat pheochromocytoma PC12 cells.
Guo DJ; Li F; Yu PH; Chan SW
Pharm Biol; 2013 Feb; 51(2):190-6. PubMed ID: 23035972
[TBL] [Abstract][Full Text] [Related]
20. Increase of Bax/ Bcl-XL ratio and arrest of cell cycle by luteolin in immortalized human hepatoma cell line.
Chang J; Hsu Y; Kuo P; Kuo Y; Chiang L; Lin C
Life Sci; 2005 Mar; 76(16):1883-93. PubMed ID: 15698865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
